Epizyme, Inc.
Epizyme Closes $32 Million Series B Financing, Led by New Investor Bay City Capital
Published in Biotech Business Week, October 19th, 2009
Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC). Joining BCC as new investors are Amgen Ventures and Astellas Venture Management. Existing investors MPM Capital and Kleiner Perkins Caufield and Byers (KPCB), which co-led the Series A round of $14 million in February 2008, made follow-on investments. Coincident with the close of the Series B, Carl Goldfischer, MD, a BCC investment partner and managing director, joins the company's Board of Directors.
"Rapid progress has been made at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- American Association for the Advancement of Science
Debut edition of Science Translational Medicine - American Thoracic Society
Being overweight super-sizes both risk and consequences of sleep-disordered breathing - BioMed Central
Antibiotic may be new stroke treatment - Child & Family Research Institute
New treatment more than doubles survival for high risk childhood leukemia - Duke University Medical Center
New approach for growing bone comes from Duke preclinical research - JAMA and Archives Journals
Genetic variation of enzyme linked with outcomes for women receiving tamoxifen - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
